A Phase II Trial of Postoperative Platinum-based Chemotherapy Plus Adjuvant and Maintenance Bevacizumab After Neoadjuvant Chemotherapy Followed by Interval Surgery in Patients With Extensive Stage IIIC or IV Ovarian, Tubal, and Peritoneal Cancer
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Carcinoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions
- 08 Jun 2021 Results assessing the safety and efficacy of adding bevacizumab to adjuvant chemotherapy with bevacizumab maintenance after neoadjuvant chemotherapy, presented at the 57th Annual Meeting of the American Society of Clinical Oncology.
- 25 Jan 2021 Status changed from recruiting to completed.
- 27 Oct 2017 Planned End Date changed from 1 May 2017 to 1 Dec 2018.